Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a diabetes drug tame asthma in overweight kids?

NCT ID NCT07622290

Disease control Sponsor: Prof Ibrahim Janahi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether metformin, a common diabetes medicine, can help control asthma in overweight or obese children aged 10 to 17. About 182 participants will receive either metformin or a placebo for 26 weeks, in addition to their usual asthma care. Researchers will measure changes in asthma control scores, lung function, and how often asthma attacks occur.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Metformin (extended-release 500 mg tablet)
What this could lead to
If it works, this could offer a new way to improve asthma control in overweight and obese children by adding metformin to their standard asthma treatment.
What could go wrong
This is a relatively small trial (182 participants) and has not yet started recruiting. Metformin is not a standard asthma drug, so it may not improve asthma control or could cause side effects like stomach upset.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 182 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

10 to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant who are capable of giving assent and parentral consent * Male/Female participant aged between10-17 years old, * overweight/obese children (Overweight and obesity are defined as BMI equal and above the 85th percentile, and BMI above the 95th percentile for age and sex, respectively). * Diagnosed with mild persistent, moderate persistent /severe asthma based on GINA guidelines within the 6 months prior to the recruitment date and having ACT score \< 20, residing in Qatar * Partcipants on standard asthma therapy for at least the last 6 months prior to the recruitment * Participant who are currently not taking part in any other interventional study Exclusion Criteria: * Non-asthma chronic lung disease * Broncho-pulmonary dysplasia * Inflammatory bowel disease * Syndromic disorders (e.g. Down's syndrome, Turner's syndrome) * Inborn errors of metabolism * Symptomatic or previously symptomatic congenital heart disease * Craniofacial abnormalities * Primary thoracic cage abnormalities * Neuromuscular disorders * Swallowing disorders * Secondary endocrinopathies causing obesity * Renal complications * Ongoing treatment for cancer * Taking metformin or GLP1 medication less than 3 months of the recruitment date * Children diagnosed with type-1 diabetes

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity-associated asthma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity-associated asthma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sidra Medicine

    Doha, Qa, 26999, Qatar